Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG PATHWAY
On map, Yellow: Drug target, Red: All disease-related 		KEGG GENES KEGG DRUG DrugBank Disease ID
1 Acute myeloid leukemia 💬
 [1] BRAF 💬 Dabrafenib 💬 Dabrafenib [1] 34 💬
2 Acute myeloid leukemia 💬
 [4] BRAF, FLT3, KIT, RAF1 💬 Sorafenib 💬 Sorafenib [2] 34, 86 💬
3 Alcoholism 💬
 [1] BRAF 💬 Dabrafenib 💬 Dabrafenib [1] 34 💬
4 Alcoholism 💬
 [2] BRAF, RAF1 💬 Sorafenib 💬 Sorafenib [2] 34, 86 💬
5 Alzheimer disease 💬
 [1] BRAF 💬 Dabrafenib 💬 Dabrafenib [1] 34 💬
6 Alzheimer disease 💬
 [2] BRAF, RAF1 💬 Sorafenib 💬 Sorafenib [2] 34, 86 💬
7 Bladder cancer 💬
 [1] BRAF 💬 Dabrafenib 💬 Dabrafenib [1] 34 💬
8 Bladder cancer 💬
 [2] BRAF, RAF1 💬 Sorafenib 💬 Sorafenib [2] 34, 86 💬
9 Breast cancer 💬
 [1] BRAF 💬 Dabrafenib 💬 Dabrafenib [1] 34 💬
10 Breast cancer 💬
 [4] BRAF, FLT4, KIT, RAF1 💬 Sorafenib 💬 Sorafenib [2] 34, 86 💬
11 cAMP signaling pathway 💬
 [1] BRAF 💬 Dabrafenib 💬 Dabrafenib [1] 34 💬
12 cAMP signaling pathway 💬
 [2] BRAF, RAF1 💬 Sorafenib 💬 Sorafenib [2] 34, 86 💬
13 Chemical carcinogenesis - reactive oxygen species 💬
 [1] BRAF 💬 Dabrafenib 💬 Dabrafenib [1] 34 💬
14 Chemical carcinogenesis - reactive oxygen species 💬
 [2] BRAF, RAF1 💬 Sorafenib 💬 Sorafenib [2] 34, 86 💬
15 Chemokine signaling pathway 💬
 [1] BRAF 💬 Dabrafenib 💬 Dabrafenib [1] 34 💬
16 Chemokine signaling pathway 💬
 [2] BRAF, RAF1 💬 Sorafenib 💬 Sorafenib [2] 34, 86 💬
17 Chronic myeloid leukemia 💬
 [1] BRAF 💬 Dabrafenib 💬 Dabrafenib [1] 34 💬
18 Chronic myeloid leukemia 💬
 [2] BRAF, RAF1 💬 Sorafenib 💬 Sorafenib [2] 34, 86 💬
19 Colorectal cancer 💬
 [1] BRAF 💬 Dabrafenib 💬 Dabrafenib [1] 34 💬
20 Colorectal cancer 💬
 [2] BRAF, RAF1 💬 Sorafenib 💬 Sorafenib [2] 34, 86 💬
21 Cushing syndrome 💬
 [1] BRAF 💬 Dabrafenib 💬 Dabrafenib [1] 34 💬
22 Cushing syndrome 💬
 [1] BRAF 💬 Sorafenib 💬 Sorafenib [2] 34, 86 💬
23 EGFR tyrosine kinase inhibitor resistance 💬
 [1] BRAF 💬 Dabrafenib 💬 Dabrafenib [1] 34 💬
24 EGFR tyrosine kinase inhibitor resistance 💬
 [4] BRAF, KDR, PDGFRB, RAF1 💬 Sorafenib 💬 Sorafenib [2] 34, 86 💬
25 Endocrine resistance 💬
 [1] BRAF 💬 Dabrafenib 💬 Dabrafenib [1] 34 💬
26 Endocrine resistance 💬
 [2] BRAF, RAF1 💬 Sorafenib 💬 Sorafenib [2] 34, 86 💬
27 Endometrial cancer 💬
 [1] BRAF 💬 Dabrafenib 💬 Dabrafenib [1] 34 💬
28 Endometrial cancer 💬
 [2] BRAF, RAF1 💬 Sorafenib 💬 Sorafenib [2] 34, 86 💬
29 ErbB signaling pathway 💬
 [1] BRAF 💬 Dabrafenib 💬 Dabrafenib [1] 34 💬
30 ErbB signaling pathway 💬
 [2] BRAF, RAF1 💬 Sorafenib 💬 Sorafenib [2] 34, 86 💬
31 Focal adhesion 💬
 [1] BRAF 💬 Dabrafenib 💬 Dabrafenib [1] 34 💬
32 Focal adhesion 💬
 [5] BRAF, FLT4, KDR, PDGFRB, RAF1 💬 Sorafenib 💬 Sorafenib [2] 34, 86 💬
33 FoxO signaling pathway 💬
 [1] BRAF 💬 Dabrafenib 💬 Dabrafenib [1] 34 💬
34 FoxO signaling pathway 💬
 [2] BRAF, RAF1 💬 Sorafenib 💬 Sorafenib [2] 34, 86 💬
35 Gastric cancer 💬
 [1] BRAF 💬 Dabrafenib 💬 Dabrafenib [1] 34 💬
36 Gastric cancer 💬
 [2] BRAF, RAF1 💬 Sorafenib 💬 Sorafenib [2] 34, 86 💬
37 Glioma 💬
 [1] BRAF 💬 Dabrafenib 💬 Dabrafenib [1] 34 💬
38 Glioma 💬
 [3] BRAF, PDGFRB, RAF1 💬 Sorafenib 💬 Sorafenib [2] 34, 86 💬
39 Hepatitis B 💬
 [1] BRAF 💬 Dabrafenib 💬 Dabrafenib [1] 34 💬
40 Hepatitis B 💬
 [2] BRAF, RAF1 💬 Sorafenib 💬 Sorafenib [2] 34, 86 💬
41 Hepatitis C 💬
 [1] BRAF 💬 Dabrafenib 💬 Dabrafenib [1] 34 💬
42 Hepatitis C 💬
 [2] BRAF, RAF1 💬 Sorafenib 💬 Sorafenib [2] 34, 86 💬
43 Hepatocellular carcinoma 💬
 [1] BRAF 💬 Dabrafenib 💬 Dabrafenib [1] 34 💬
44 Hepatocellular carcinoma 💬
 [2] BRAF, RAF1 💬 Sorafenib 💬 Sorafenib [2] 34, 86 💬
45 Insulin signaling pathway 💬
 [1] BRAF 💬 Dabrafenib 💬 Dabrafenib [1] 34 💬
46 Insulin signaling pathway 💬
 [2] BRAF, RAF1 💬 Sorafenib 💬 Sorafenib [2] 34, 86 💬
47 Long-term depression 💬
 [1] BRAF 💬 Dabrafenib 💬 Dabrafenib [1] 34 💬
48 Long-term depression 💬
 [2] BRAF, RAF1 💬 Sorafenib 💬 Sorafenib [2] 34, 86 💬
49 Long-term potentiation 💬
 [1] BRAF 💬 Dabrafenib 💬 Dabrafenib [1] 34 💬
50 Long-term potentiation 💬
 [2] BRAF, RAF1 💬 Sorafenib 💬 Sorafenib [2] 34, 86 💬
51 MAPK signaling pathway 💬
 [1] BRAF 💬 Dabrafenib 💬 Dabrafenib [1] 34 💬
52 MAPK signaling pathway 💬
 [7] BRAF, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1 💬 Sorafenib 💬 Sorafenib [2] 34, 86 💬
53 Melanoma 💬
 [1] BRAF 💬 Dabrafenib 💬 Dabrafenib [1] 34 💬
54 Melanoma 💬
 [3] BRAF, PDGFRB, RAF1 💬 Sorafenib 💬 Sorafenib [2] 34, 86 💬
55 mTOR signaling pathway 💬
 [1] BRAF 💬 Dabrafenib 💬 Dabrafenib [1] 34 💬
56 mTOR signaling pathway 💬
 [2] BRAF, RAF1 💬 Sorafenib 💬 Sorafenib [2] 34, 86 💬
57 Natural killer cell mediated cytotoxicity 💬
 [1] BRAF 💬 Dabrafenib 💬 Dabrafenib [1] 34 💬
58 Natural killer cell mediated cytotoxicity 💬
 [2] BRAF, RAF1 💬 Sorafenib 💬 Sorafenib [2] 34, 86 💬
59 Neurotrophin signaling pathway 💬
 [1] BRAF 💬 Dabrafenib 💬 Dabrafenib [1] 34 💬
60 Neurotrophin signaling pathway 💬
 [2] BRAF, RAF1 💬 Sorafenib 💬 Sorafenib [2] 34, 86 💬
61 Non-small cell lung cancer 💬
 [1] BRAF 💬 Dabrafenib 💬 Dabrafenib [1] 34 💬
62 Non-small cell lung cancer 💬
 [3] BRAF, RAF1, RET 💬 Sorafenib 💬 Sorafenib [2] 34, 86 💬
63 Pancreatic cancer 💬
 [1] BRAF 💬 Dabrafenib 💬 Dabrafenib [1] 34 💬
64 Pancreatic cancer 💬
 [2] BRAF, RAF1 💬 Sorafenib 💬 Sorafenib [2] 34, 86 💬
65 Parathyroid hormone synthesis, secretion and action 💬
 [1] BRAF 💬 Dabrafenib 💬 Dabrafenib [1] 34 💬
66 Parathyroid hormone synthesis, secretion and action 💬
 [2] BRAF, RAF1 💬 Sorafenib 💬 Sorafenib [2] 34, 86 💬
67 Pathways in cancer 💬
 [1] BRAF 💬 Dabrafenib 💬 Dabrafenib [1] 34 💬
68 Pathways in cancer 💬
 [7] BRAF, FLT3, FLT4, KIT, PDGFRB, RAF1, RET 💬 Sorafenib 💬 Sorafenib [2] 34, 86 💬
69 Pathways of neurodegeneration - multiple diseases 💬
 [1] BRAF 💬 Dabrafenib 💬 Dabrafenib [1] 34 💬
70 Pathways of neurodegeneration - multiple diseases 💬
 [2] BRAF, RAF1 💬 Sorafenib 💬 Sorafenib [2] 34, 86 💬
71 Progesterone-mediated oocyte maturation 💬
 [1] BRAF 💬 Dabrafenib 💬 Dabrafenib [1] 34 💬
72 Progesterone-mediated oocyte maturation 💬
 [2] BRAF, RAF1 💬 Sorafenib 💬 Sorafenib [2] 34, 86 💬
73 Prostate cancer 💬
 [1] BRAF 💬 Dabrafenib 💬 Dabrafenib [1] 34 💬
74 Prostate cancer 💬
 [3] BRAF, PDGFRB, RAF1 💬 Sorafenib 💬 Sorafenib [2] 34, 86 💬
75 Proteoglycans in cancer 💬
 [1] BRAF 💬 Dabrafenib 💬 Dabrafenib [1] 34 💬
76 Proteoglycans in cancer 💬
 [3] BRAF, KDR, RAF1 💬 Sorafenib 💬 Sorafenib [2] 34, 86 💬
77 Rap1 signaling pathway 💬
 [1] BRAF 💬 Dabrafenib 💬 Dabrafenib [1] 34 💬
78 Rap1 signaling pathway 💬
 [6] BRAF, FLT4, KDR, KIT, PDGFRB, RAF1 💬 Sorafenib 💬 Sorafenib [2] 34, 86 💬
79 Regulation of actin cytoskeleton 💬
 [1] BRAF 💬 Dabrafenib 💬 Dabrafenib [1] 34 💬
80 Regulation of actin cytoskeleton 💬
 [3] BRAF, PDGFRB, RAF1 💬 Sorafenib 💬 Sorafenib [2] 34, 86 💬
81 Renal cell carcinoma 💬
 [1] BRAF 💬 Dabrafenib 💬 Dabrafenib [1] 34 💬
82 Renal cell carcinoma 💬
 [2] BRAF, RAF1 💬 Sorafenib 💬 Sorafenib [2] 34, 86 💬
83 Serotonergic synapse 💬
 [1] BRAF 💬 Dabrafenib 💬 Dabrafenib [1] 34 💬
84 Serotonergic synapse 💬
 [2] BRAF, RAF1 💬 Sorafenib 💬 Sorafenib [2] 34, 86 💬
85 Thyroid cancer 💬
 [1] BRAF 💬 Dabrafenib 💬 Dabrafenib [1] 34 💬
86 Thyroid cancer 💬
 [2] BRAF, RET 💬 Sorafenib 💬 Sorafenib [2] 34, 86 💬
87 Vascular smooth muscle contraction 💬
 [1] BRAF 💬 Dabrafenib 💬 Dabrafenib [1] 34 💬
88 Vascular smooth muscle contraction 💬
 [2] BRAF, RAF1 💬 Sorafenib 💬 Sorafenib [2] 34, 86 💬

Back to top